[
    [
        {
            "time": "2023-10-05",
            "original_text": "Health Care Select Sector SPDR Fund Experiences Big Inflow",
            "features": {
                "keywords": [
                    "Health Care Select Sector",
                    "SPDR Fund",
                    "Big Inflow"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Select Sector SPDR Fund Experiences Big Inflow",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "AbbVie's rheumatoid arthritis drug succeeds in late-stage study",
            "features": {
                "keywords": [
                    "AbbVie",
                    "rheumatoid arthritis",
                    "drug",
                    "late-stage study",
                    "succeeds"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie's rheumatoid arthritis drug succeeds in late-stage study",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis",
            "features": {
                "keywords": [
                    "Upadacitinib",
                    "Monotherapy",
                    "Phase 3 Study",
                    "Rheumatoid Arthritis",
                    "Endpoints"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]